Margaret Gatti-Mays
Margaret Gatti-Mays
Explore linked clinical trials.1 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer | Anatomic Stage IV Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma | Recruiting | Phase 1 / Phase 2 | 2026-07-23 | NCT06026657 |